论文部分内容阅读
目的观察西妥昔单抗与奥沙利铂/5-FU/FA联合治疗转移性结直肠癌的近期疗效及毒性反应。方法对11例转移性结直肠癌(MCRC)患者采用西妥昔单抗与奥沙利铂/5-FU/FA化疗联合方案,应用2周期后评价近期疗效及毒性反应。西妥昔单抗首次推荐剂量为400 mg/m~2,以后每周剂量为250 mg/m~2,奥沙利铂/5-FU/FA化疗剂量采用FOLFOX4方案。结果11例患者均完成西妥昔单抗连续6周用药,奥沙利铂/5-FU/FA化疗2周期(每2周重复1次),无CR病例,2例PR(18.18%),4例SD(36.36%),5例PD(45.45%),疾病控制(PR+SD)率54.55%。治疗过程中出现的毒性反应为3～4度的痤疮样皮疹,另外有恶心、呕吐、腹痛和虚弱,2～3度白细胞下降。全组患者无过敏反应。结论西妥昔单抗可提高肿瘤对放化疗的敏感性。采用西妥昔单抗与奥沙利铂联合治疗11例转移性结直肠癌患者,取得初步疗效和安全性观察,且不因联合化疗而增加毒性反应,耐受性良好。
Objective To observe the short-term curative effect and toxicity of cetuximab plus oxaliplatin / 5-FU / FA in the treatment of metastatic colorectal cancer. Methods Eleven patients with metastatic colorectal cancer (MCRC) were treated with cetuximab and oxaliplatin / 5-FU / FA chemotherapy. The efficacy and toxicity of 2 cycles were evaluated. Cetuximab first recommended dose of 400 mg / m ~ 2, after a weekly dose of 250 mg / m ~ 2, oxaliplatin / 5-FU / FA chemotherapy dose using FOLFOX4 program. Results All of the 11 patients received cetuximab for 6 weeks, 2 cycles of oxaliplatin / 5-FU / FA chemotherapy (once every 2 weeks), no CR, 2 PR (18.18%), 4 cases of SD (36.36%), 5 cases of PD (45.45%), disease control (PR + SD) rate of 54.55%. Toxicity in the course of treatment of 3 to 4 degrees of acne-like rash, in addition to nausea, vomiting, abdominal pain and weakness, 2 to 3 degrees of leukopenia. All patients without allergic reaction. Conclusion Cetuximab can increase the sensitivity of tumor to radiotherapy and chemotherapy. Eleven patients with metastatic colorectal cancer were treated with cetuximab and oxaliplatin, and the initial curative effect and safety were observed. The combination of cetuximab and oxaliplatin did not increase the toxic reaction due to combined chemotherapy, and was well tolerated.